Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Trial details
- Registry ID
- NCT04869943
- Phase
- Phase 3
The FDA approved Exemestane on 21 Oct 1999.
Drug identity checked against registry records
Also recorded as Mestane
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 | VERU | Phase 3 | Terminated | 2024-01-09Actual |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 | OLMA | Phase 3 | Active not recruiting | 2026-10-31Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1999-10-21Day | Exemestane | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020753", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["AROMASIN"], "active_ingredients": ["EXEMESTANE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19991021", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |